medigraphic.com
Instituto Nacional de Salud Pública

2016, Number 2

<< Back Next >>

salud publica mex 2016; 58 (2)

Cancer burden in Mexico: urgent challenges to be met

Lazcano-Ponce E, Mohar-Betancourt A, Meneses-García A, Hernández-Ávila M

Language: English
References: 14
Page: 101-103
PDF size: 170.41 Kb.


Text Extraction

Primary prevention of cancer was initiated with the introduction of Hepatitis B vaccine in the 80’s.1 However, in primary prevention of cancer at the worldwide level has been relatively recent. Intervention-action initiatives began at the global level in 2003 with the WHO Framework Convention on Tobacco Control, which was the first treaty negotiated under WHO guidance and as of today includes 168 countries.


REFERENCES

  1. The Gambia Hepatitis Intervention Study. The Gambia Hepatitis Study Group. Cancer Res 1987;47(21):5782-5787.

  2. Wipfli H, Stillman F, Tamplin S, da Costa e Silva VL, Yach D, Samet J. Achieving the Framework Convention on Tobacco Control’s potential by investing in national capacity. Tob Control 2004;13(4):433-437.

  3. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004;328(7455):1519.

  4. Krugman S. The prevention of viral hepatitis. Ann Clin Res 1976;8(3): 216-220.

  5. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. Broad Spectrum HPV Vaccine Study, A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372(8):711-723.

  6. Michalas SP. The Pap test: George N. Papanicolaou (1883-1962). A screening test for the prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol 2000;90(2):135-138.

  7. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community- based randomised controlled trial. Lancet 2011;378(9806):1868-1873.

  8. Monticciolo D, Morris E. Unreliable Conclusions of Breast Cancer Screening, Incidence, and Mortality. JAMA Intern Med 2016;176(1):140-141.

  9. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87-108.

  10. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev 2016;25(1):16-27.

  11. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, et al. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol 2012;30(1):88-109.

  12. Schottenfeld D, Beebe-Dimmer J. The cancer burden attributable to biologic agents. Ann Epidemiol 2015;25(3):183-187.

  13. Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol 2015;16(14):1405-1438.

  14. Parkin DM. The role of cancer registries in cancer control. Int J Clin Oncol 2008;13(2):102-111.




2020     |     www.medigraphic.com